In March 2026, the Galician Agency for Health Technology Assessment (Avalia-t) is working on several HTAs, including in cardiovascular, dermatology, e-health, gastrointestinal, interventional radiology, robotic surgery, in-vitro diagnostics, peripheral vascular, neurology and neurosurgery, neuromodulation, and some other fields.

Ever wondered what a day in Market Access really feels like? It’s the constant dance between urgent requests, imperfect evidence, and the realities of European reimbursement systems that rarely match corporate ambitions. One moment you're justifying a premium price; the next, you're piecing together models from single-arm studies, hoping they hold up in HTA-driven markets. Along the way, you try to connect payer value with hospital incentives, even when the pieces don’t quite align. Without early, cross-functional strategic thinking, Market Access becomes reactive instead of by design. Read more in our Partner's Blog.

In March 2026, the Decision Forum for the "New Methods" framework made a favorable coverage decision for intermittent negative pressure therapy (FlowOx) for conditions related to reduced blood circulation in the extremities

In March 2026, the HTA body of Tuscany Regional Healthcare released four rapid HTA reports (three new assessments and one reassessment) on medical devices in the cardiovascular, peripheral vascular, interventional radiology, and orthopedics fields.

On 2 March 2026, NHS England and the Department of Health and Social Care (DHSC) announced the next phase in the transfer of national commissioning functions, subject to parliamentary approval. From April 2027, integrated care boards (ICBs) will assume responsibility for a broader set of services, including selected specialised services (in addition to those already delegated), most components of screening programs, and public health functions. Following the expected abolition of NHS England in 2027, DHSC will take on the remaining national commissioning responsibilities, including highly specialised services and High Cost devices, as well as maintaining national service specifications and clinical commissioning policies.

On March 6, 2026, the German Bundestag adopted amendments to the hospital reform. The core objectives of the reform remain unchanged: consolidating services, increasing specialization, and thereby improving the quality of healthcare delivery. The adjustments primarily aim to ensure the practical implementation of the measures, with a particular focus on maintaining inpatient care, especially standard and emergency care, in rural areas.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Xie et al. examined how diagnostic test accuracy (DTA) studies can better support economic modelling of new diagnostic tests.

In January 2026, the Belgian Health Care Knowledge Centre (KCE) published one Health Technology Assessment report on blood-based biomarkers in mild traumatic brain injury and two Health Service Research (HSR) reports addressing chronic pain management and the shift from inpatient to day and ambulatory care.

MTRC is pleased to announce the appointment of Mr. Steffen Uffenorde as Director of Market Access & HEOR. He brings senior leadership experience in health economics, reimbursement strategy, and market access across the medical technology sector. Mr. Uffenorde has led health economics and market access initiatives at Boston Scientific, Abbott, BD, and St. Jude Medical, supporting the reimbursement and adoption of cardiovascular and other technologies across EMEA healthcare systems.

In February 2026, Health Technology Wales (HTW) accomplished one full appraisal on capsule sponge devices for the detection of Barrett’s esophagus and early-stage esophageal cancer. Additionally, two Med Tech-related Topic Exploration Reports were published in the urology and gynecology fields.

In February 2026, the Danish Healthcare Quality Institute (DHQI) released a document outlining the criteria for “triaging” clinical guideline recommendations to health economic analysis. The criteria aim to identify recommendations with potentially significant clinical and resource implications that should undergo health economic evaluation and be considered by the DHQI Council for possible nationwide implementation.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, D'Oca et al. analyzed current practices in the PICO scoping process used to define the scope of Joint Clinical Assessments under the EU HTA Regulation.